Abstract
Background Preclinical evidence suggests that diazepam enhances hippocampal γ-aminobutyric acid (GABA) signalling and normalises a psychosis-relevant cortico-limbic-striatal circuit. Hippocampal network dysconnectivity, particularly from the CA1 subfield, is evident in people at clinical high-risk for psychosis (CHR-P), representing a potential treatment target. This study aimed to forward-translate this preclinical evidence.
Methods In this randomised, double-blind, placebo-controlled study, 18 CHR-P individuals underwent resting-state functional magnetic resonance imaging twice, once following a 5mg dose of diazepam and once following a placebo. They were compared to 20 healthy controls (HC) who did not receive diazepam/placebo. Functional connectivity (FC) between the hippocampal CA1 subfield and the nucleus accumbens (NAc), amygdala, and ventromedial prefrontal cortex (vmPFC) was calculated. Mixed-effects models investigated the effect of group (CHR-P placebo/diazepam vs. HC) and condition (CHR-P diazepam vs. placebo) on CA1-to-region FC.
Results In the placebo condition, CHR-P individuals showed significantly lower CA1-vmPFC (Z=3.17, PFWE=0.002) and CA1-NAc (Z=2.94, PFWE=0.005) FC compared to HC. In the diazepam compared to placebo condition, CA1-vmPFC FC was significantly increased (Z=4.13, PFWE=0.008) in CHR-P individuals, and both CA1-vmPFC and CA1-NAc FC were normalised to HC levels. In contrast, compared to HC, CA1-amygdala FC was significantly lower contralaterally and higher ipsilaterally in CHR-P individuals in both the placebo and diazepam conditions (lower: placebo Z=3.46, PFWE=0.002, diazepam Z=3.33, PFWE=0.003; higher: placebo Z=4.48, PFWE<0.001, diazepam Z=4.22, PFWE<0.001).
Conclusions This study demonstrates that diazepam can partially restore hippocampal CA1 dysconnectivity in CHR-P individuals, suggesting that modulation of GABAergic function might be useful in the treatment of this clinical group.
Competing Interest Statement
AAG has received consulting fees from Alkermes, Lundbeck, Takeda, Roche, Lyra, Concert, Newron and SynAgile, and research funding from Newron and Merck. SCRW has recently received research funding from Boehringer Ingelheim and GE Healthcare to perform investigator-led research. AE has received consultancy fees from Leal Therapeutics. GM has received consulting fees from Boehringer Ingelheim. The remaining authors have no disclosures to declare
Clinical Trial
NCT06190483
Funding Statement
This research was funded by the Wellcome Trust and The Royal Society (202397/Z/16/Z to GM) and the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the Welcome Trust, NIHR or the Department of Health and Social Care. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received ethical approval from the National Health Service UK Research Ethics Committee (18/LO/0618) and each participant gave written informed consent. While the study received ethical clearance as not a Clinical Trial of an Investigational Medicinal Product by the EU directive 2001/20/EC it was registered on clinicaltrials.gov (NCT06190483)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the authors
